High Resting Heart Rates Are Associated with Early Posthospitalization Mortality in Low Ejection Fraction Patients
Authors:
- Andreas HainAHAndreas Hain
- Nikolai BuschNBNikolai Busch
- Said Elias WaezsadaSWSaid Elias Waezsada
- Julie HutterJHJulie Hutter
- Patrick KahlePKPatrick Kahle
- Malte KunissMKMalte Kuniss
- Thomas NeumannTNThomas Neumann
- Tsyuoshi MasudaTMTsyuoshi Masuda
- Horst O. EsserHEHorst O. Esser
- Christian HammCHChristian Hamm
- Johannes SperzelJSJohannes Sperzel
Open Access
- 20 May 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (10) , 2901
Abstract
Guideline-directed medical therapy (GDMT) is crucial in reducing mortality in patients with heart failure with heart rate lowering by a beta blocker (BB) being an important therapeutic concept. We aimed to assess the usefulness of a wearable cardioverter/defibrillator (WCD) to provide detailed information about heart rate for managing patients with reduced left ventricular ejection fraction (LVEF) and symptoms of heart failure and to correlate mortality with the mean heart rate. A total of 4509 consecutive patients (mean age: 59 + 13 years, 88% male) were analyzed retrospectively. All patients had reduced LVEF and were prescribed a WCD for protection from sudden cardiac death (SCD) during GDMT uptitration awaiting LVEF recovery. The device continuously measured nighttime and daytime HR at the beginning and end of WCD use. Patients who died during wear time had significantly higher HRs compared with survivors: daytime beginning of use (BOU), 80 ± 15 bpm vs. 76 ± 13, p < 0.01; nighttime BOU, 76 ± 14 vs. 69 ± 13, p < 0.0001; daytime end of use (EOU), 84 ± 20 vs. 73 ± 13, p < 0.0001; nighttime EOU, 80 ± 20 vs. 65 ± 12, p < 0.0001). In conclusion, HR monitoring with a WCD yields important prognostic information and may assist in optimal usage of BB in patients with low LVEF.Keywords
This publication has 14 references indexed in Scilit:
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2017
- Wearable Cardioverter DefibrillatorsCardiology in Review, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Heart rate as a target of treatment of chronic heart failureJournal of Cardiology, 2012
- Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialThe Lancet, 2010
- Rationale and Design of a Randomized, Double-Blind, Placebo-Controlled Outcome Trial of Ivabradine in Chronic Heart Failure: The Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT)European Journal of Heart Failure, 2009
- Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart FailureAnnals of Internal Medicine, 2009
- Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialThe Lancet, 2008
- Heart-Rate Profile during Exercise as a Predictor of Sudden DeathNew England Journal of Medicine, 2005
- Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II TrialCirculation, 2001